MDM2 and cancer: To the date, most of the pharmacological approaches aiming at reactivating p53 in cancer cells have focused on the interaction interface between p53 and Mdm2 or Mdmx30, and most protein–protein interaction (PPI) inhibitors are peptides or antibody drugs.